Berger Montague Reminds GRAIL, Inc. (GRAL) Investors With Substantial Losses to Inquire About a Securities Fraud Class Action by August 4, 2026

Philadelphia, Pennsylvania--(Newsfile Corp. - July 30, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) ("GRAIL" or the "Company") on behalf of investors who purchased or acquired GRAIL common stock during the period from May 13, 2025 through February 19, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired GRAIL common stock during the Class Period may, no later than August 4, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Headquartered in Menlo Park, Calif., GRAIL is a life sciences company that develops multi-cancer early detection tests. The Company's lead product, the Galleri test, uses a blood-based genomic analysis to screen for dozens of cancers simultaneously. According to the suit, while Defendants publicly championed the NHS-Galleri trial and maintained an optimistic narrative around the Galleri platform, they concealed that the trial's design and follow-up duration were materially inadequate to demonstrate the study's primary endpoint. On February 19, 2026, GRAIL announced that the NHS-Galleri Trial had failed to achieve a statistically significant reduction in late-stage cancers. The Company attributed the shortfall in part to the trial needing a longer follow-up period to yield valid comparisons. GRAIL's stock plummeted approximately 50.55% on the next trading day, falling from a close of $101.53 per share on February 19, 2026 to a close of $50.21 per share on February 20, 2026. If you are a GRAIL investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267) 764-4865. About Berger Montague Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. For more information or to discuss your rights, please contact: Andrew Abramowitz Berger Montague (215) 875-3015 [email protected] Caitlin Adorni Berger Montague (267) 764-4865 [email protected] To view the source version of this press release, please visit https://www.newsfilecorp.com/release/307237 Source: Berger Montague